首页> 外文期刊>Autoimmunity >Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production.
【24h】

Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production.

机译:共聚物-I通过促进1型免疫反应和自身抗体产生而加剧自身免疫性关节炎。

获取原文
获取原文并翻译 | 示例
           

摘要

Copolymer-I (COP-I) is an unique immune regulatory polymer that has been shown to suppress experimental autoimmune encephalomyelitis (EAE) and is a treatment option for multiple sclerosis (MS). To investigate whether its immune suppressive effects can be extended to other autoimmune diseases, we treated mice with COP-I during the induction of collagen-induced arthritis (CIA). Our results show that COP-I treatment exacerbated CIA, leading to faster onset, more severe and longer-lasting disease. The mechanisms underlying the exacerbation of CIA by COP-I treatment include enhanced activation and inflammatory cytokine production by autoreactive T cells and elevated production of autoreactive antibodies. In addition, germinal center response was significantly enhanced by COP-I treatment. Thus, great caution should be taken when COP-I is to be used in MS patients with other autoimmune complications or its potential therapeutic effects are to be extended beyond autoimmune demyelinating diseases.
机译:共聚物-I(COP-1)是一种独特的免疫调节聚合物,已显示可抑制实验性自身免疫性脑脊髓炎(EAE),并且是多发性硬化症(MS)的治疗选择。为了研究其免疫抑制作用是否可以扩展到其他自身免疫性疾病,我们在诱导胶原诱导的关节炎(CIA)期间用COP-1治疗了小鼠。我们的结果表明,COP-1治疗加重了CIA,导致更快的发作,更严重的疾病和更持久的疾病。 COP-1治疗加重CI​​A的潜在机制包括自身反应性T细胞的活化增强和炎性细胞因子的产生以及自身反应性抗体的产生增加。另外,COP-1治疗显着增强了生发中心反应。因此,当COP-1用于有其他自身免疫并发症的MS患者时,应格外小心,否则其潜在的治疗作用应扩展到自身免疫脱髓鞘疾病以外。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号